Stock Ratings / Health Care / COAG / earnings

ALVO (58) VIR (31) MAZE (45) MESO (60) ⌘ Pro Terminal →

Hemab Therapeutics Holdings Inc. (COAG) Next Earnings Date & Expected ±12.5% Move

$40.42 +4.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $40.71

Hemab Therapeutics Holdings Inc. (COAG) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.89B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $40.71 (+0.71%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COAG)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY COAG SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (23% of score)

FRED Regime × Technicals: 54% of 52W Range • RSI-14 at 67.2 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$31.62-4.9% Next Q

Q2 (-2Q)

Grade C-$30.07+14.4% Next Q

Q3 (-1Q)

Grade C-$34.40+17.5% Next Q

Current

Grade D+$40.42-0.2% Hist 90D α

Trajectory: D (49) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the COAG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, COAG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($37.90) or 200D SMA ($36.78) invalidates the momentum regime and cuts Target Base ($40.24) toward Bear Floor ($31.39).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $COAG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “COAG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$5.05 Expected Swing

MODEL EARNINGS SETUP GAUGE

COAG Quantitative Pre-Earnings Setup: 57/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (57/100)Model Risk Weight (43/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	$0	$0	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COAG)

✓Walkthrough of COAG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

COAG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.88%▲ RESISTANCE BREAKOUT

2026-10-30O $40.34H $42.85L $39.38C $40.42VOL 765.5K

RES: $29.22SUP: $28.10SMA50: $37.90SMA200: $36.78

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

COAG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 COAG Butterfly Map → + Track COAG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on COAG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for COAG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for COAG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COAG)

Health Care Rank #251 of 1016 ⚔️ ALVO vs COAG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (COAG vs. ALVO, VIR, MAZE, MESO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Hemab Therapeutics Holdings Inc. (COAG) ranks #251 by composite RQD confidence (57/100, grade D+) and #274 by equity capitalization ($1.89B). Within this direct 5-issuer industry benchmark cohort, COAG leads on earnings valuation at N/A trailing P/E, while VIR leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. MESO currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with COAG at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
COAG ACTIVE Hemab Therapeutics Holdings Inc.	D+	57/100	—	—	—	+4.99%	$1.89B	Benchmark Subject
ALVO Alvotech	D+	58/100	—	—	—	-1.01%	$1.91B	/alvo-vs-coag →
VIR Vir Biotechnology Inc.	E	31/100	—	96.0%	-35.0%	-1.51%	$2.01B	/vir-vs-coag →
MAZE Maze Therapeutics Inc.	D	45/100	—	—	-35.0%	+0.63%	$1.77B	/maze-vs-coag →
MESO Mesoblast Limited	C-	60/100	—	—	—	+17.03%	$2.04B	/meso-vs-coag →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002114044

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hemab Therapeutics Holdings Inc. (COAG) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, COAG closed FY2025 with $194.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$194.8M	—

3. COAG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is COAG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Hemab Therapeutics Holdings Inc. (NASDAQ: COAG) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $40.42 (+4.99% 1D, market cap $1.89B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, COAG ranks #251 in composite RQD confidence.

How does COAG compare to ALVO and VIR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), COAG carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALVO (Alvotech) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.91B) and VIR (Vir Biotechnology Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.01B). Among the 5-stock peer group, COAG leads on earnings multiple (N/A) while VIR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for COAG?

Per COAG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002114044), Hemab Therapeutics Holdings Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $194.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is COAG trading relative to its 50-day, 200-day, and 52-week technical levels?

COAG last traded at $40.42 (+4.99% on volume of 1,195,923 shares), positioning the stock +6.65% above its 50-day simple moving average ($37.90) and +9.90% above its 200-day simple moving average ($36.78). Across its 52-week range of $23.00 to $55.42, COAG sits at the 53.7% percentile with a 14-day RSI of 67.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($35.37 to $45.47).

COAG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is COAG's next earnings date?

Based on SEC filing cadence, Hemab Therapeutics Holdings Inc. (COAG)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is COAG stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for COAG, spanning a range between $35.37 and $45.47.

Direct Sub-Reports: COAG RQD Cockpit COAG 12M Forecast COAG Earnings & Move COAG Dividends & DRIP COAG Insiders & 13F COAG Whale Options COAG Profit Sankey COAG News & Why